Regeneron Pharmaceuticals Inc (REGN)

369.15
7.14 1.97
NASDAQ : Health Care
Prev Close 362.01
Open 361.80
Day Low/High 359.50 / 370.49
52 Wk Low/High 329.09 / 605.93
Volume 972.79K
Avg Volume 852.90K
Exchange NASDAQ
Shares Outstanding 105.47M
Market Cap 38.91B
EPS 6.20
P/E Ratio 53.86
Div & Yield N.A. (N.A)

Latest News

Jim Cramer's 'Mad Money' Recap: How to Handle Your Finances at Any Age

Jim Cramer's 'Mad Money' Recap: How to Handle Your Finances at Any Age

You need to have money invested in the stock market, whatever your age, Cramer says.

What Regeneron's CEO Thinks About Drug Pricing Under Trump

What Regeneron's CEO Thinks About Drug Pricing Under Trump

Leonard Schleifer says his company has worked under six administrations and hopes to continue his mission for a fair balance on drug prices.

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

Teva Shares Lower on Third-Quarter Results

Teva Shares Lower on Third-Quarter Results

Teva's revenue was helped by its acquisition of Allergan's generics business in the third quarter, though sales nonetheless missed estimates.

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Six Thoughts on President Trump and the Durability of the Biotech Stock Rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

Regeneron (REGN) Stock Closed Up on Q3 Results

Regeneron (REGN) Stock Closed Up on Q3 Results

Regeneron (REGN) said third-quarter profit beat analysts' estimates.

Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer

Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer

Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.

Markets Await October Jobs Report Friday

Markets Await October Jobs Report Friday

The October jobs report is released on Friday, November 4th at 8:30 a.m. Eastern.

'Mad Money' Lightning Round: On Biotechs, Wait Until After the Election

'Mad Money' Lightning Round: On Biotechs, Wait Until After the Election

Biotech's uncertain, but semiconductors are a bright spot in this market, Jim Cramer says.

Jim Cramer's 'Mad Money' Recap: Seven Reasons Why the Market Dropped Today

Jim Cramer's 'Mad Money' Recap: Seven Reasons Why the Market Dropped Today

From politics and oil to Apple, there was no good news for the market, says Jim Cramer.

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.

Regeneron Pharmaceuticals Becomes #28 Most Shorted Nasdaq 100 Component, Replacing Xilinx

Regeneron Pharmaceuticals Becomes #28 Most Shorted Nasdaq 100 Component, Replacing Xilinx

The most recent short interest data has been released for the 10/14/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

What to Watch in Sanofi's Third-Quarter Results

What to Watch in Sanofi's Third-Quarter Results

Slower declines in diabetes drug sales and an acceleration in new oncology treatment Praluent are key to a good quarter for the French drugs maker.

FDA Puts Hold on Regeneron Pain-Drug Study

FDA Puts Hold on Regeneron Pain-Drug Study

Shares of Regeneron Pharmaceuticals were lower Monday after The Food and Drug Administration put a drug study on hold.

Jim Cramer's 'Mad Money' Recap: Here's Where Money Can Still Be Made

Jim Cramer's 'Mad Money' Recap: Here's Where Money Can Still Be Made

Don't focus on just one day of trading, Jim Cramer says.

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

On days like this, the money just keeps sloshing around.

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

- U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety -

The New #33 Most Shorted Nasdaq 100 Component: Regeneron Pharmaceuticals

The New #33 Most Shorted Nasdaq 100 Component: Regeneron Pharmaceuticals

The most recent short interest data has been released for the 09/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Teva And Regeneron Announce Global Collaboration To Develop And Commercialize Fasinumab, An Investigational NGF Antibody For Chronic Pain

Teva And Regeneron Announce Global Collaboration To Develop And Commercialize Fasinumab, An Investigational NGF Antibody For Chronic Pain

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Regeneron Pharmaceuticals, Inc.

Allergan's Dealmaking Continues With Vitae Takeout

Allergan's Dealmaking Continues With Vitae Takeout

The $639 million deal marks the the third purchase for Brent Saunders since early August.

Regeneron Pharmaceuticals Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Sirius XM Holdings

Regeneron Pharmaceuticals Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Sirius XM Holdings

The most recent short interest data has been released for the 08/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.